Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 28

Results For "NFI"

1028 News Found

Avallano appoints Michael A. Ibara as Chief Strategy Officer
News | July 03, 2024

Avallano appoints Michael A. Ibara as Chief Strategy Officer

Ibara will drive AI-powered clinical research innovation


DKSH and Kimberly-Clark Partner to Launch Huggies Baby and Childcare Products in Cambodia
Supply Chain | July 02, 2024

DKSH and Kimberly-Clark Partner to Launch Huggies Baby and Childcare Products in Cambodia

DKSH’s Business Unit Consumer Goods further capitalizes on its position to strengthen the consumer health, nutrition, and baby care categories


Orchid Pharma and Cipla collaborate to launch antibiotic Cefepime-Enmetazobactam in India
News | June 29, 2024

Orchid Pharma and Cipla collaborate to launch antibiotic Cefepime-Enmetazobactam in India

The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR


Sun Pharma’s Utreglutide demonstrates significant weight loss at the American Diabetes Association 84th Scientific Sessions
News | June 25, 2024

Sun Pharma’s Utreglutide demonstrates significant weight loss at the American Diabetes Association 84th Scientific Sessions

GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity


Ascentage Pharma closes US$ 75 million equity investment by Takeda
News | June 24, 2024

Ascentage Pharma closes US$ 75 million equity investment by Takeda

Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO


Truqap plus Faslodex approved in the EU for patients with advanced ER-positive breast cancer
News | June 22, 2024

Truqap plus Faslodex approved in the EU for patients with advanced ER-positive breast cancer

Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population


Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC
Drug Approval | June 22, 2024

Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC

Second FDA approval for KRAZATI - reinforcing its potential across tumor types


Cipla EU to invest an additional € 3 million in Ethris
News | June 19, 2024

Cipla EU to invest an additional € 3 million in Ethris

Cipla had earlier invested € 15 million in Ethris in 2022


FDA approves Lenire device by Neuromod for tinnitus treatment option for US veterans
Medical Device | June 19, 2024

FDA approves Lenire device by Neuromod for tinnitus treatment option for US veterans

Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government


Imfinzi approved in the US for endometrial cancer
Drug Approval | June 17, 2024

Imfinzi approved in the US for endometrial cancer

Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy